July 22, 2021Open Access

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The RP2D for ceralasertib plus carboplatin was established as ceralasertib 40 mg once daily on days 1-2 administered with carboplatin AUC5 every 3 weeks, with pharmacokinetic and pharmacodynamic studies confirming pharmacodynamic modulation and preliminary evidence of antitumor activity observed.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Yap et al. (Thu,) studied this question.

synapsesocial.com/papers/69d7573ab54ccf0cfef30e83 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-21-1032

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

13 + 3 ≠ (Rolling) 62008 · 10 citations
2Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers2018 · 34 citations
3ATR: an essential regulator of genome integrity2008 · 1,780 citations
4Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer2013 · 122 citations
5The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer<i>in vivo</i>2015 · 244 citations

Me gusta

Guardar

Ver artículo completo